Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Despite there is a wide range of antidepressants available, with various mechanisms of actions, the efficacy of current therapeutic options is yet satisfactory. Previous shreds of evidence have indicated that genetics, cognitive, neuroendocrine, as well as personality factors, are all intrinsically linked and contribute to the diversity of treatment outcomes. We, therefore, sought to investigate this hypothesis in this study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>Based on 610 samples treated with a selection of serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), noradrenergic and specific serotonergic antidepressant (NaSSA) or tricyclic antidepressant (TCA), we compared the therapeutic effects of these four classes of drugs by survival analyses. Pharmacogenomic and survival analyses were carried out to explore the hereditary factors for curative effect and the accumulation of genetic factors was further discussed through pathway analysis and the global test. We built a machine learning-based prediction model that integrates genetic and non-genetic factors (including cognition, endocrinology, personality intelligence) to distinguish drug efficacy in single class drug situations. The values of the non-genetic makers after 6 weeks' treatment were collected to evaluate the efficacy of the model.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Our results from the 6-week antidepressant therapeutic study indicated that SSRI and SNRI are better treatments than those of TCA and NaSSA in the Chinese population. Among all possible paired single-agent survival analyses, citalopram and venlafaxine were more effective than mirtazapine. Allele C carriers at rs6354 (<em>SLC6A4</em>) and allele G carriers at rs12150214 (<em>SLC6A4</em>) were significantly prone to poorer treatment response to fluoxetine. Besides, the combination of three loci (rs929377-rs6191-rs32897) located in HPA pathway was significantly associated with the treatment outcome of fluoxetine. In female MDD patients, the minor allele of rs6323 and rs1137070 on the <em>MAOA</em> gene likely lead to a worse response to venlafaxine. Furthermore, genetic variants linked to drug efficacy tended to concentrate on the neurotrophin pathway in depressed patients comorbid with anxiety. From multivariate models, more severe cognitive deficits, psychopathic personality and lower levels of operational intelligence, and higher levels of cortisol predicted worse response status with SSRI or SNRI after 6-week treatment. Notably, genetic factors in the multi-dimensional prediction model for both classes of drugs include loci in <em>HTR2A</em> and <em>CRHBP</em> genes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>SSRI and SNRI are more suitable for the treatment of Chinese people with depression. <em>SLC6A4</em> genetic variants, as well as HPA pathway, play an important role in the fluoxetine antidepressant therapeutic response while the polymorphism of <em>MAOA</em> gene involved in the pharmacological action of venlafaxine among female MDD patients. The presence of anxiety in MDD patients was related to the neurotrophin pathway. Genetic, cognitive, neuroendocrine, and personality intelligence factors combined have an ensemble impact on the medication effect of patients with major depression, leading to more precise and personalized medicine for specific groups of people.</p>

Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder

Molecular, Functional, and Structural Imaging of Major Depressive Disorder

A Joint Study of Whole Exome Sequencing and Structural MRI Analysis in Major Depressive Disorder.

The association of oxytocin with major depressive disorder: role of confounding effects of antidepressants

Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications

Association of APC and REEP5 Gene Polymorphisms with Major Depression Disorder and Treatment Response to Antidepressants in a Han Chinese Population

The roles of extracellular vesicles in major depressive disorder

Association Between FoxO1, A2M, and TGF-β1, Environmental Factors, and Major Depressive Disorder

The Link Between Long Noncoding RNAs and Depression.

Molecular pathways of major depressive disorder converge on the synapse

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression

Linking individual variability in functional brain connectivity to polygenic risk in major depressive disorder

Pathogenesis of depression: Insights from human and rodent studies

Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential

Key Risk Genes Identified From the Postmortem Brain of Patients With Major Depressive Disorder and Their Potential Clinical Applications

Major depressive disorder: hypothesis, mechanism, prevention and treatment

Links among Genetic Variants and Hierarchical Brain Structural and Functional Networks for Antidepressant Treatment: A Multivariate Study.

Vulnerability and plasticity of monoamine neurotransmitter systems in affective and personality disorders

An Investigation into the Association Between Dopamine Receptor D1 Multilocus Genetic Variation, Multiparametric Magnetic Resonance Imaging, and Antidepressant Treatment